Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies다양한 질병 조절 요법으로 치료받는 다발성 경화증 환자에서 mRNA COVID-19 백신의 면역원성과 안전성Article Published on 2022-01-012022-09-11 Journal: Neurotherapeutics : the journal of the American So [Category] SARS, 진단, 치료기술, [키워드] Alemtuzumab Cladribine correlation COVID-19 COVID-19 vaccination detect develop Disease-modifying therapies drugs evaluated fatigue fingolimod Hospitalization humoral humoral immune response Humoral response IgG immune response immunoassay immunogenicity injection injection site Microparticle MONITOR mRNA COVID-19 vaccine mRNA COVID-19 vaccines Multiple multiple sclerosis Natalizumab Ocrelizumab Pain Patient patients treated positively correlated reduce reported Safe SARS-CoV-2 antibodies SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 nucleoprotein second dose Side effect significantly lower therapy treated Treatment vaccination was tested [DOI] 10.1007/s13311-021-01165-9 PMC 바로가기 [Article Type] Article
Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey다발성 경화증 치료 및 관리에 대한 COVID-19의 영향: 유럽 다발성 경화증 치료 및 연구 위원회의 결과Article Published on 2022-01-012022-09-11 Journal: Multiple sclerosis (Houndmills, Basingstoke, Engla [Category] SARS, 치료기술, [키워드] Access to care activated adopted Alemtuzumab anti-CD20 Care CD20 changes in Cladribine Clinical practice Committee coronavirus disease Coronavirus disease-19 country COVID-19 COVID-19 emergency dimethyl fumarate disease-modifying treatment Emergency Europe European fingolimod fumarate Glatiramer Impact interferons lymphopenia management Modification Multiple multiple sclerosis Natalizumab overcome Patient promoted reported Result Safe sclerosis Spread Telemedicine Teriflunomide therapy Treatment unique with COVID-19 [DOI] 10.1177/13524585211005339 PMC 바로가기 [Article Type] Article
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosisocrelizumab, alemtuzumab 및 cladribine 후 CD19 B 세포 재증식: 다발성 경화증에서 SARS-CoV-2 예방 접종에 대한 의미Article Published on 2022-01-012022-09-12 Journal: Multiple sclerosis and related disorders [Category] SARS, 진단, [키워드] Alemtuzumab B cell B-cell CD19 CD20 Cladribine clinical trial Control Controlled determine dosing interval exhibited extension facilitate Frequency inhibit lymphocyte maintain MOST Multiple multiple sclerosis occurred Ocrelizumab Relapse relapsing rituximab SARS-CoV-2 vaccination Seroconversion seroconvert Standard therapy Tablet Treatment Trial vaccination [DOI] 10.1016/j.msard.2021.103448 PMC 바로가기 [Article Type] Article
Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis다발성 경화증 환자에서 BNT162b2 mRNA 백신 2회 접종 후 코로나19 혈청학적 반응에 대한 클라드리빈의 효과Article Published on 2022-01-012022-09-12 Journal: Multiple sclerosis and related disorders [Category] MERS, SARS, 진단, [키워드] antibody Antibody Response Antibody titers BNT162b2 mRNA vaccine BNT162b2 vaccine Cladribine Cladribine tablets Consensus correlation COVID-19 COVID-19 pandemic COVID-19 vaccination develop dose Effect HCs healthy control immunomodulatory independent interferon lymphocyte counts mRNA vaccine Multiple multiple sclerosis Participants Patient patients patients treated physician positive serology Protective response SARS-CoV-2 SARS-CoV-2 vaccine second dose serology Spike protein the SARS-CoV-2 treated Treatment vaccination Vaccine vaccine dose vaccine efficacy was tested [DOI] 10.1016/j.msard.2021.103343 PMC 바로가기 [Article Type] Article
Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continuesCOVID-19 대유행이 계속되는 동안 모발 세포 백혈병의 진단 및 치료Review Published on 2022-01-012022-09-12 Journal: Blood reviews [Category] 변종, 진단, 치료법, [키워드] Avoiding B-cell BRAF BRAF inhibitor Chemotherapy Cladribine Complete COVID-19 COVID-19 pandemic COVID-19 vaccination Dabrafenib disease driven by Efficacy Hairy cell Hairy cell leukemia Ibrutinib indolent leukemia malignancy Minimal residual disease Moxetumomab pasudotox Mutation patients persistence Prevent purine remained rituximab T-cells Toxicity Trametinib treated Treatment unique Vemurafenib [DOI] 10.1016/j.blre.2021.100888 PMC 바로가기 [Article Type] Review
Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study화이자 BNT162b2 코로나19 백신 접종 후 다발성 경화증 환자의 체액성 면역 반응: 최대 6개월 단면 연구Observational Study Published on 2021-12-152022-09-12 Journal: Journal of neuroimmunology [Category] MERS, SARS, 임상, 진단, [키워드] Alemtuzumab Appropriate Cladribine COVID-19 COVID-19 vaccination COVID19 cross-sectional demonstrated dimethyl fumarate Disease modifying treatments fingolimod healthy subject healthy subjects help Humoral immunity IgG IgG antibody IgG response immune response Multiple multiple sclerosis Natalizumab Ocrelizumab Patient response Teriflunomide treated treated patients Treatment vaccination Vaccine [DOI] 10.1016/j.jneuroim.2021.577746 PMC 바로가기 [Article Type] Observational Study
Opportunities and Obstacles Associated With Sequential Immune Reconstitution Therapy for Multiple Sclerosis: A Case Reportarticle Published on 2021-12-082024-09-02 Journal: Frontiers in Neurology [Category] 대상포진, [키워드] Alemtuzumab Case report Cladribine immune reconstitution therapy multiple sclerosis [DOI] 10.3389/fneur.2021.664596 PMC 바로가기 [Article Type] article
SARS-CoV-2 infection after alemtuzumab in a multiple sclerosis patient: milder disease symptoms in comparison with coinfected relatives: a case report and review of the literature다발성 경화증 환자에서 alemtuzumab 후 SARS-CoV-2 감염: 동시 감염 친척에 비해 가벼운 질병 증상: 증례 보고 및 문헌 검토Review Published on 2021-12-012022-09-12 Journal: Neurological Sciences [Category] MERS, SARS, 진단, [키워드] Alemtuzumab Anti-S1 benefit Case report Cladribine Complication coronavirus COVID-19 pandemic disease symptom drug female had no iatrogenic immunodeficiency Immunodepleting agents Infection literature lymphopenic mother Multiple multiple sclerosis Patient patients treated positive reported risk SARS-CoV-2 SARS-CoV-2 antibodies SARS-COV-2 infection SARS-CoV-2 virus severe complication severe disease significantly Symptom tested treated Treatment [DOI] 10.1007/s10072-021-05567-7 PMC 바로가기 [Article Type] Review
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis다발성 경화증에서 COVID-19 중증도와 질병 수정 요법의 연관성41 Published on 2021-11-092022-09-12 Journal: Neurology [Category] MERS, SARS, 진단, [키워드] 95% CI 95% confidence interval Acetate adjusted adjusted odds ratio Admission admitted to ICU age Alemtuzumab analyzed artificial ventilation association Characteristics Cladribine Cohort coronavirus disease Coronavirus disease 2019 country covariate covariates COVID-19 COVID-19 cases COVID-19 severity cross-sectional design death demographic demonstrated died dimethyl fumarate disability EDSS EDSS score examined fumarate Glatiramer Glatiramer acetate higher risk Hospitalization Hospitalized ICU ICU admission immunosuppressive include increased risk indication intensive care intensive care unit interferon internal and external International Logistic regression Multiple multiple sclerosis Natalizumab objective Ocrelizumab Older age outcome outcomes Patient phenotype reflected required restriction Result risk factor rituximab scale sclerosis severe coronavirus disease severe COVID-19 severity Sex Siponimod status Stratification therapy Ventilation were assessed with COVID-19 [DOI] 10.1212/WNL.0000000000012753 PMC 바로가기 [Article Type] 41
Severe Multiple Sclerosis Relapse After COVID-19 Vaccination: A Case ReportNeurology Published on 2021-08-102022-11-01 Journal: Frontiers in Neurology [Category] COVID-19, [키워드] Acute relapse BNT162b2 vaccine Case report Cladribine clinical condition COVID-19 COVID-19 vaccination COVID-19 vaccination programme COVID-19 vaccine COVID-19 vaccines Diagnosis implementation IMPROVE Italy knowledge lesions limbs Methylprednisolone MRI mRNA Multiple multiple sclerosis National neurological Neurological symptom paraesthesia Patient pharmacological receiving recommendations Relapse report sclerosis South the patient the vaccine therapy weakness [DOI] 10.3389/fneur.2021.721502 PMC 바로가기 [Article Type] Neurology